STRIVERDI RESPIMAT (olodaterol), bronchodilator

No improvement in clinical benefit demonstrated in obstructive pulmonary disease in comparison with other long-acting bronchodilators

• STRIVERDI RESPIMAT has a Marketing Authorisation as a maintenance bronchodilator treatment of chronic obstructive pulmonary disease (COPD).

• Its efficacy has been demonstrated versus placebo in terms of change in FEV1 but not in terms of reduction in exacerbations, dyspnoea and improvement in the quality of life.

• There are no data that can be used to rate olodaterol by comparison with other long-acting bronchodilators.